Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in Patients With Metastatic Breast Cancer
Breast cancer remains one of the most lethal forms of cancer despite advances in early detection and treatment. A patient's hormone receptor (HR) status, which includes estrogen receptor (ER) and progesterone receptor (PR) status, conveys both prognostic and predictive implications for patients with breast cancer. Up to 75 percent of breast tumors rely on ER signaling to grow. Targeting this pathway with anti-estrogen therapy has been shown in trials to have a clear clinical benefit in the treatment of this subset of breast cancer patients. Understanding HR status at the time of diagnosis, occurrence of metastasis and throughout the course of therapy can help inform patient treatment and, ultimately, has the potential to influence patient outcome.
The
"We are encouraged that the results of this study further support the validity of
"These findings could ultimately have significant implications in how we treat advanced stage breast cancer patients," said
The ultimate goal of CTC evaluation is to assist physicians with making treatment decisions, such as the role of anti-estrogen therapy. The Columbia study shows that CTCs afford diagnostic results that are comparable to tumor tissue.
About
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as
CONTACT: Corporate Communications Contact: For Media:Source:Melanie Sollid-Penton ,The Ruth Group msollid@theruthgroup.com (646) 536-7023For Investors :David Burke ,The Ruth Group dburke@theruthgroup.com (646) 536-7009
News Provided by Acquire Media